Mark F. Bear, Picower Institute, MIT, MA, USA
Marlene Behrmann, Carnegie Mellon University, PA, USA
Thomas Bourgeron, Institut Pasteur, Paris, France
Nils Brose, Max Planck Institute for Experimental Medicine, Göttingen, Germany
Jacqueline N. Crawley, NIMH/NIH, Washington, DC, USA
Ricardo Dolmetsch, Stanford University, CA, USA
Michael D. Ehlers, Pfizer, CT, USA
Guoping Feng, McGovern Institute, MIT, MA, USA
Daniel Geschwind, UCLA, CA, USA
Michael E. Greenberg, Harvard Medical School, MA, USA
Takao Hensch, Harvard Medical School, MA, USA
Kimberly M. Huber, UT Southwestern Medical Center, TX, USA
Ami Klin, Children’s Healthcare of Atlanta and Emory University School of Medicine, USA
Pat Levitt, USC, CA, USA
Alea A. Mills, Cold Spring Harbor Laboratory, NY, USA
Hannah Monyer, University and DKFZ Heidelberg, Germany
Declan G. Murphy, King's College London, UK
Paul H. Patterson, CalTech, CA, USA
Robert T. Schultz, Children's Hospital of Philadelphia and University of Pennsylvania, PA, USA
Morgan Sheng, Genentech, CA, USA
Alcino Silva, UCLA, CA, USA
Matthew W. State, Yale University, CT, USA
Thomas C. Südhof, Stanford University, CA, USA
Mriganka Sur, MIT, MA, USA
Christopher A. Walsh, Harvard Stem Cell Institute, MA, USA
An official 2011 SFN satellite meeting, Autism Spectrum Disorders: From Mechanisms to Therapies, will focus on recent advances in understanding the neural basis of autism spectrum disorders (ASD). It is estimated that 1.5 million individuals in the U.S. and tens of millions worldwide are affected by autism and that 1 in 110 children are diagnosed with an autism spectrum disorders each year. While the causes of autism are not clear, in recent years, significant progress has been made towards unraveling the underlying disease etiology and candidate mechanisms.
The aim of this meeting is to bring together key researchers working on autism spectrum disorders at multiple levels, with a specific goal of considering how current basic research findings and candidate mechanisms can be directed towards therapies and treatments.
The topics that will be discussed include: autism genetics; synaptic and circuit level mechanism; cognitive mechanisms; animal models; moving from models and mechanisms to therapeutics.
In typical style for Cell Press Symposia, this meeting will be organized for a high level of interaction and discussion. This three day meeting will include talks from leading researchers in the field, as well as moderated round table discussion workshops and poster sessions, to encourage dialogue and exchange of ideas.